Larson SM, Walthers CM, Ji B, Ghafouri SN, Naparstek J, Trent J, Chen JM, Roshandell M, Harris C, Khericha M, Schweppe T, Berent-Maoz B, Gosliner SB, Almaktari A, Ceja MA, Allen-Auerbach MS, Said J, Nawaly K, Mead M, de Vos S, Young PA, Oliai C, Schiller GJ, Timmerman JM, Ribas A, Chen YY
Cancer Discov 2023 Mar 1;13(3):580-597. doi: 10.1158/2159-8290.CD-22-0964. PMID: 36416874 Free PMC Article

Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy.

Carreau NA, Armand P, Merryman RW, Advani RH, Spinner MA, Herrera AF, Ramchandren R, Hamid MS, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair SM, Barta SK, Nathan S, Karmali R, Torka P, David K, Lansigan F, Persky D, Godfrey J, Chavez JC, Xia Y, Diefenbach C
Br J Haematol 2020 Oct;191(1):44-51. Epub 2020 May 19 doi: 10.1111/bjh.16756. PMID: 32430944

CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.

Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S, Bianchi R, Richard M, Schoenle A, Nicolini V, Diggelmann S, Limani F, Schlenker R, Hüsser T, Richter W, Bray-French K, Hinton H, Giusti AM, Freimoser-Grundschober A, Lariviere L, Neumann C, Klein C, Umaña P
Clin Cancer Res 2018 Oct 1;24(19):4785-4797. Epub 2018 May 1 doi: 10.1158/1078-0432.CCR-18-0455. PMID: 29716920

See all (11)

Recent clinical studies

Etiology

Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant.

Pasvolsky O, Bassett RL, Ghanem S, Cuglievan B, Tewari P, Hosing C, Srour S, Ramdial J, Mahadeo KM, Khazal S, Petropoulos D, Popat U, Qazilbash M, Kebriaei P, Champlin R, Shpall EJ, Nieto Y
BMC Cancer 2023 Dec 20;23(1):1258. doi: 10.1186/s12885-023-11712-6. PMID: 38124057 Free PMC Article

Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma.

Chu Y, Gardenswartz A, Diorio C, Marks LJ, Lowe E, Teachey DT, Cairo MS
Best Pract Res Clin Haematol 2023 Mar;36(1):101442. Epub 2023 Feb 2 doi: 10.1016/j.beha.2023.101442. PMID: 36907635

Response to hyperfractionated accelerated radiotherapy in chemotherapy-refractory non-Hodgkin lymphoma.

Kim DW, Lee G, Lee H, Mahal AR, Lam MB, Ng AK
Leuk Lymphoma 2020 Jun;61(6):1428-1434. Epub 2020 Feb 26 doi: 10.1080/10428194.2020.1719096. PMID: 32102580

Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).

Morschhauser F, Flinn IW, Advani R, Sehn LH, Diefenbach C, Kolibaba K, Press OW, Salles G, Tilly H, Chen AI, Assouline S, Cheson BD, Dreyling M, Hagenbeek A, Zinzani PL, Jones S, Cheng J, Lu D, Penuel E, Hirata J, Wenger M, Chu YW, Sharman J
Lancet Haematol 2019 May;6(5):e254-e265. Epub 2019 Mar 29 doi: 10.1016/S2352-3026(19)30026-2. PMID: 30935953

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH, Dunbar M, Zhu M, Peale F, Ross JA, Gressick L, Desai M, Kim SY, Verdugo M, Humerickhouse RA, Gordon GB, Gerecitano JF
J Clin Oncol 2017 Mar 10;35(8):826-833. Epub 2017 Jan 17 doi: 10.1200/JCO.2016.70.4320. PMID: 28095146 Free PMC Article

See all (57)

Diagnosis

Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity.

Breen WG, Young JR, Hathcock MA, Kowalchuk RO, Thorpe MP, Bansal R, Khurana A, Bennani NN, Paludo J, Bisneto JV, Wang Y, Ansell SM, Peterson JL, Johnston PB, Lester SC, Lin Y
Blood Cancer J 2023 Aug 18;13(1):127. doi: 10.1038/s41408-023-00895-7. PMID: 37591834 Free PMC Article

Long-term follow up of relapsed/refractory non-Hodgkin lymphoma patients treated with single-agent selinexor - a retrospective, single center study.

Ben Barouch S, Bhella S, Kridel R, Kukreti V, Prica A, Crump M, Kuruvilla J
Leuk Lymphoma 2022 Aug;63(8):1879-1886. Epub 2022 Mar 9 doi: 10.1080/10428194.2022.2047674. PMID: 35263209

Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma.

Tong C, Zhang Y, Liu Y, Ji X, Zhang W, Guo Y, Han X, Ti D, Dai H, Wang C, Yang Q, Liu W, Wang Y, Wu Z, Han W
Blood 2020 Oct 1;136(14):1632-1644. doi: 10.1182/blood.2020005278. PMID: 32556247 Free PMC Article

Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use.

Hughes ME, Landsburg DJ, Rubin DJ, Schuster SJ, Svoboda J, Gerson JN, Namoglu E, Nasta SD
Clin Lymphoma Myeloma Leuk 2019 Dec;19(12):791-798. Epub 2019 Sep 28 doi: 10.1016/j.clml.2019.09.612. PMID: 31648953

Investigational therapies targeting CD37 for the treatment of B-cell lymphoid malignancies.

Witkowska M, Smolewski P, Robak T
Expert Opin Investig Drugs 2018 Feb;27(2):171-177. Epub 2018 Jan 15 doi: 10.1080/13543784.2018.1427730. PMID: 29323537

See all (19)

Therapy

Nicotinamide enhances natural killer cell function and yields remissions in patients with non-Hodgkin lymphoma.

Cichocki F, Zhang B, Wu CY, Chiu E, Day A, O'Connor RS, Yackoubov D, Simantov R, McKenna DH, Cao Q, Defor TE, Janakiram M, Wangen R, Cayci Z, Snyder N, Kumar A, Grzywacz B, Hwang J, Geffen Y, Miller JS, Maakaron J, Bachanova V
Sci Transl Med 2023 Jul 19;15(705):eade3341. doi: 10.1126/scitranslmed.ade3341. PMID: 37467318 Free PMC Article

CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma.

Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.

Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, Barnes JA, O'Brien SM, Chávez JC, Duell J, Rosenwald A, Crombie JL, Ufkin M, Li J, Zhu M, Ambati SR, Chaudhry A, Lowy I, Topp MS
Lancet Haematol 2022 May;9(5):e327-e339. Epub 2022 Apr 1 doi: 10.1016/S2352-3026(22)00072-2. PMID: 35366963 Free PMC Article

Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma.

Bröske AE, Korfi K, Belousov A, Wilson S, Ooi CH, Bolen CR, Canamero M, Alcaide EG, James I, Piccione EC, Carlile DJ, Dimier N, Umaña P, Bacac M, Weisser M, Dickinson M
Blood Adv 2022 Feb 8;6(3):1025-1037. doi: 10.1182/bloodadvances.2021005954. PMID: 34941996 Free PMC Article